Paper Details

  1. Home
  2. Paper Details

Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism.

Author: BastianelliCarlo, BenagianoGiuseppe, BrosensIvo, FarrisManuela, RosatoElena

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review explores the metabolic effects of combined oral contraceptives (COCs) on healthy women. New generations of progestins in COCs are generally considered safer than older ones, with fewer androgenic, estrogenic, or glucocorticoid related side effects. The review focuses on metabolic changes related to carbohydrates, lipids, and bone mineral content. Overall, the metabolic effects of modern COCs, especially when combined with natural estrogens, are minimal and should not cause significant concern in healthy women.
Paper Details　
Original Abstract of the Article :
The risk-benefit profile of any pharmacologic agent must be evaluated against risks connected with the events to be avoided. This is especially true in the case of hormonal contraception, not intended to combat a disease. Over the six decades during which their use has progressively expanded, the ri...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17512433.2017.1271708

データ提供：米国国立医学図書館（NLM）

Pharmacodynamics of Combined Estrogen-Progestin Oral Contraceptives

This study delves into the field of hormonal contraception and investigates the metabolic effects of combined estrogen-progestin oral contraceptives (COCs). The researchers focus on the metabolic changes occurring during the use of modern COC combinations, comparing new generations of progestins to classic compounds. Their objective is to provide an updated assessment of the metabolic effects of COCs, particularly the impact of newer progestin formulations on carbohydrate, lipid, and bone mineral metabolism.

The study concludes that newer generations of progestins, when combined with natural estrogens, have minimal metabolic effects. The researchers highlight the improved safety profile of these newer formulations, emphasizing the need for large-scale studies to confirm their safety and efficacy. They also emphasize the importance of individualized risk-benefit assessments when prescribing COCs.

Navigating the Complexities of Hormonal Contraception: A Desert Journey

This study, like a camel traversing the vast desert of hormonal contraception, explores the intricate metabolic effects of combined estrogen-progestin oral contraceptives (COCs). The researchers offer valuable insights into the evolving landscape of COC formulations, highlighting the improved safety profile of newer generations of progestins.

Understanding Metabolic Effects of COCs: A Detailed Look

This study, like a detailed map of a desert oasis, provides a comprehensive overview of the metabolic effects of COCs. The researchers' focus on comparing newer progestin formulations with classic compounds is valuable for understanding the potential impact of COCs on carbohydrate, lipid, and bone mineral metabolism. Their emphasis on individualized risk-benefit assessments underscores the importance of tailoring treatment decisions to individual patients.

Dr.Camel's Conclusion

This research, like a camel navigating the shifting sands of hormonal contraception, provides a valuable update on the metabolic effects of combined estrogen-progestin oral contraceptives (COCs). The study highlights the improved safety profile of newer progestin formulations and emphasizes the importance of individualized risk-benefit assessments to ensure optimal patient outcomes.

Date :
  1. Date Completed 2017-03-13
  2. Date Revised 2017-03-13
Further Info :

Pubmed ID

27977304

DOI: Digital Object Identifier

10.1080/17512433.2017.1271708

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.